Asia PacificENPublic regulatory overview
South Korea
Market Overview Population: Approximately 52 million (2024); aging population accelerating Healthcare System: Universal health insurance (National Health Insurance Service, NHIS);...
Updated: 2026-05-04
You are viewing the public excerpt. During the limited-time free period, sign in to view the complete country report.
Reference approval strategy
FDA / CE / MDSAP / NMPA benefits for this market
These factors can reduce evidence-building work, support review confidence, or shape the filing strategy. They do not automatically replace local registration.
US FDA
510(k) / De Novo / PMAModerate benefitFDA evidence is useful technical and clinical support, but the local authority still performs an independent review.
Likely benefit
- Use FDA review summaries, clearance or approval letters, test reports, clinical evidence, and software or electrical-safety files as support.
- May reduce technical questions when the intended use, model scope, and evidence package match the local filing.
Limit
- Does not remove local holder, language, labeling, fee, import, or post-market obligations.
EU CE
MDR / IVDRModerate benefitCE evidence provides a strong technical-file template but does not replace the local review.
Likely benefit
- Reuse MDR/IVDR technical documentation, clinical evaluation, ISO testing, GSPR or essential-principles mapping, labeling, and PMS evidence.
- Often helps build CSDT, IMDRF, or local-format technical files faster.
Limit
- Does not replace local registration or local representative responsibilities outside the CE-recognized route.
MDSAP
Single QMS auditModerate benefitMDSAP can help with QMS credibility, especially when issued by a recognized auditing organization.
Likely benefit
- Reduce duplicate quality-system audits and support ISO 13485, CAPA, complaints, supplier controls, design controls, and production controls.
- Most useful when the market accepts MDSAP directly or when the application depends on QMS maturity.
Limit
- Does not authorize product sale and does not replace safety, performance, or clinical evidence.
China NMPA
China registration / filingDossier reuse onlyThe NMPA certificate itself has limited effect, but ISO/IEC-aligned test reports, clinical evidence, risk files, and PMS data can be reused after gap assessment.
Likely benefit
- Use NMPA approval as prior-registration evidence, China market history, and product-maturity support.
- Convert ISO/IEC-aligned testing, clinical, risk-management, and PMS documents from the NMPA file into the local dossier.
Limit
- Do not assume automatic recognition; China-only GB/YY evidence may need retesting or restructuring.
AI Citation Summary
- Country: South Korea
- Product line: Medical devices
- Regulator / source: Regulatory Maturity: High. MFDS (Ministry of Food and Drug Safety, 식품의약품안전처) has a well-established regulatory system; has recently strengthened guidance on digital health devices (SaMD) and AI-based medical devices, aligning with IMDRF; review efficiency is relatively high and timelines are reasonably predictable.
- Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
- Typical timeline: Regulatory Maturity: High. MFDS (Ministry of Food and Drug Safety, 식품의약품안전처) has a well-established regulatory system; has recently strengthened guidance on digital health devices (SaMD) and AI-based medical devices, aligning with IMDRF; review efficiency is relatively high and timelines are reasonably predictable.
- Key fees: Market Characteristics: Market size approximately KRW 10 trillion (approx. USD 7.5 billion) in 2023 — Asia's fourth-largest medical device market. Imports account for approximately 50%. The government actively promotes medical device exports but maintains strict regulation of imports. Innovative medical devices (AI, digital health) are growing rapidly.
- Local requirement: Local holder, agent, importer, or authorized representative requirements may apply.
- Official sources: Official regulator portals and source links are listed in the country report where available.
- Last verified: 2026-05-04
- Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
- Preferred citation: MedTech Atlas
Market Overview
- Population: Approximately 52 million (2024); aging population accelerating
- Healthcare System: Universal health insurance (National Health Insurance Service, NHIS); dual public and private hospital system; high level of medical technology; a well-developed medical tourism industry. Domestic medical device manufacturers (Samsung Medison, Osstem, etc.) are strong competitors.
- Market Characteristics: Market size approximately KRW 10 trillion (approx. USD 7.5 billion) in 2023 — Asia's fourth-largest medical device market. Imports account for approximately 50%. The government actively promotes medical device exports but maintains strict regulation of imports. Innovative medical devices (AI, digital health) are growing rapidly.
- Regulatory Maturity: High. MFDS (Ministry of Food and Drug Safety, 식품의약품안전처) has a well-established regulatory system; has recently strengthened guidance on digital health devices (SaMD) and AI-based medical devices, aligning with IMDRF; review efficiency is relatively high and timelines are reasonably predictable.
Regulatory Authority
- Competent Authority: MFDS (Ministry of Food and Drug Safety, 식품의약품안전처)
- Official Portals: https://www.mfds.go.kr; Medical Device Registration System: UDIPORTAL / 수입품목허가시스템 (Import Item License System)
- Key Regulations:
- Medical Devices Act (의료기기법, enacted 2003, multiple revisions)
- Enforcement Decree and Enforcement Rules of the Medical Devices Act
- Regulations on Licensing, Approval, and Review of Medical Devices (MFDS Notice)
- Medical Device GMP Standard (품질관리기준)
- Guidance Principles for AI-Based Medical Device Software (2021)
Device Classification System
| Local Classification | Risk Level | EU/FDA Equivalent | Description |
|---|---|---|---|
| Class 1 | Lowest risk | EU Class I / FDA Class I | Notification (신고, declaration/filing) system; simple procedure |
| Class 2 | Low-moderate risk | EU Class IIa / FDA Class II | License (허가) system or Certification (인증) system |
| Class 3 | Moderate-high risk | EU Class IIb-III / FDA Class II-III | License (허가) system; MFDS direct review |
| Class 4 | Highest risk | EU Class III / FDA PMA | License (허가) system; most stringent review |
Note: Product classification is determined by the MFDS Medical Device Classification Catalogue. Certain Class 2 products may follow an "인증 (Certification)" pathway (analogous to European NB certification), which is comparatively faster; others must follow the MFDS direct license pathway.
Registration Pathways
During the limited-time free period, sign in or register to view the complete medical device country report.